Schedule 13G ownership disclosure

Compass Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 20454B104

Event date: 2025-10-22

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 4,673,550.00 · Class: 2.7%

  • BVF I GP LLC

    Shares: 4,673,550.00 · Class: 2.7%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 3,396,894.00 · Class: 2.0%

  • BVF II GP LLC

    Shares: 3,396,894.00 · Class: 2.0%

  • Biotechnology Value Trading Fund OS LP

    Shares: 542,486.00 · Class: 0.3%

  • BVF Partners OS Ltd.

    Shares: 542,486.00 · Class: 0.3%

  • BVF GP HOLDINGS LLC

    Shares: 8,070,444.00 · Class: 4.7%

  • BVF PARTNERS L P/IL

    Shares: 8,750,000.00 · Class: 5.1%

  • BVF INC/IL

    Shares: 8,750,000.00 · Class: 5.1%

  • LAMPERT MARK N

    Shares: 8,750,000.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-002825
Form type
SCHEDULE 13G
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Oct 29, 2025
Reporting period
Oct 22, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub